A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Short Title: C6461013

Enrollment Status: Recruiting

NCT #: NCT07222800

Specialty Area: Oncology

Condition Studied: Metastatic Colorectal Cancer

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To study treatment options for people with metastatic colorectal cancer that has not been treated yet for is advanced stage. This study compares a new investigational medicine given with standard chemotherapy to a commonly used approved treatment given with chemotherapy. The goal of the study is to better understand how well the new treatment works and how safe it is, with the aim of improving care for people with advanced colorectal cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with metastatic (stage IV) colorectal cancer that has not been treated previously for metastatic disease
Healthy enough to receive combination chemotherapy in the opinion of the treating investigator

What's Involved

Participation in the study will include:

Treatment of either a new medicine called PF-08634404 combined with standard chemotherapy or the approved drug bevacizumab with chemotherapy given by intravenous (IV) infusion in cycles
Regular visits for monitoring, tests, and follow-up visits during and after treatment

Principal Investigator

Harry Menon, DO

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT07222800

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews